Collectively, these data identify a subset of tumor-restraining, pro-immunogenic lymphocytes—CD8+GzmB+, CD4+IFN-γ+, CD103+ TRM, and CD69+ memory cells—whose activation predicts favorable outcomes and treatment responsiveness. The gene discussed is ITGAE; the disease is neoplasm.